Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT04601285 Terminated - Clinical trials for Advanced Solid Tumors

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors. This study is divided into 3 periods: dose escalation period, dose expansion period, and clinical expansion period.

NCT ID: NCT04577703 Completed - Clinical trials for Advanced Solid Tumors

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Start date: February 8, 2014
Phase: Phase 1
Study type: Interventional

This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors

NCT ID: NCT04565275 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ICP-192 in Patients With Advanced Solid Tumors

Start date: February 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.

NCT ID: NCT04518137 Terminated - Clinical trials for Advanced Solid Tumors

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

Start date: April 9, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts

NCT ID: NCT04492488 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Start date: May 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.

NCT ID: NCT04487236 Recruiting - Clinical trials for Advanced Solid Tumors

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors. The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

NCT ID: NCT04481009 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Start date: August 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts.

NCT ID: NCT04471675 Recruiting - Clinical trials for Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel

Start date: December 2, 2020
Phase: Phase 1
Study type: Interventional

This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The aim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of albumin-bound formulation of docetaxel for intravenous infusion in patients with advanced solid tumors.

NCT ID: NCT04450901 Active, not recruiting - Clinical trials for Advanced Solid Tumors

Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors

Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, open-label, multicenter, dose-escalation/dose-expansion study of YBL-006, in participants with Advanced Solid Tumors. This multicenter study will be conducted in approximately 11-14 participants in the dose escalation phase, and approximately 39-76 participants in dose expansion phase.

NCT ID: NCT04449874 Recruiting - Colorectal Cancer Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Start date: July 29, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.